Blood plasma levels of monocyte-associated protein CD14, which is involved in activating proinflammatory interleukin-6 signaling (49) and is known to be upregulated in severe COVID-19 (50), is also lowered after treatment. This evidence concerns the gene IL6 and COVID-19.